Quality of Life Assessment in Patients Who Are Under Surveillance for IPMN
Intraduktaalisen Papillaarisen Musinoosisen Neoplasian Vuoksi Seurannassa Olevien Potilaiden elämänlaatu
1 other identifier
observational
300
0 countries
N/A
Brief Summary
Over 500 patients were participating in the IPMN follow up between september 2014 and august 2016 at the Helsinki University Hospital. In this study we are going to determine the effects of the IPMN surveillance on the quality of life and anxiety levels of the patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2017
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 7, 2017
CompletedFirst Posted
Study publicly available on registry
April 27, 2017
CompletedStudy Start
First participant enrolled
May 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2019
CompletedApril 27, 2017
April 1, 2017
1.3 years
April 7, 2017
April 26, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Change in the quality of life and anxiety
15D quality of life and STAI -questionnaire
Before and 3 months after IPMN follow up MRI
Interventions
Follow up with MRI and laboratory blood tests
Eligibility Criteria
All patients under IPMN follow up
You may qualify if:
- all patients under IPMN surveillance
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Nieminen H, Roine R, Ristimaki A, Lantto E, Valimaa N, Kirveskari E, Sintonen H, Haglund C, Seppanen H. Health-related quality of life and anxiety levels among patients under surveillance for intraductal papillary mucinous neoplasm. BMC Gastroenterol. 2023 Jan 16;23(1):14. doi: 10.1186/s12876-023-02639-0.
PMID: 36647007DERIVED
Study Officials
- PRINCIPAL INVESTIGATOR
Heini Nieminen
Helsinki Universtity Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- licensed physician
Study Record Dates
First Submitted
April 7, 2017
First Posted
April 27, 2017
Study Start
May 1, 2017
Primary Completion
August 31, 2018
Study Completion
December 31, 2019
Last Updated
April 27, 2017
Record last verified: 2017-04
Data Sharing
- IPD Sharing
- Will not share
Data will not be shared.